

An Exploratory Analysis of Predictors of Concordance between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta

Analyse exploratoire des prédicteurs de la concordance entre les recommandations de remboursement du Programme commun d'évaluation des médicaments et les décisions subséquentes de l'Ontario, de la Colombie-Britannique et de l'Alberta

MICHAEL J. ZORATTI, FENG XIE, KRISTIAN THORLUND, NICOLA ALLEN AND MITCHELL LEVINE

Appendix 1: Complete list of Common Drug Review (CDR) recommendations and corresponding provincial decisions (Ontario, British Columbia and Alberta)

Drug	CDR recommendation	Provincial decisions		
		Ontario	British Columbia	Alberta
Remicade (Infliximab)	Negative	None	Negative	Negative
Adempas (Riociguat)	Positive	Positive	Negative	Negative
Cerdelga (Eliuglstat)	Positive	None	None	None
Cinqair (Reslizumab)	Positive	None	None	None
Diacomit (Stiripentol)	Positive	None	Positive	Positive
Difcid (Fidaxomicin)	Negative	None	Positive	Positive
Epclusa (Sofosbuvir/velpatasvir)	Positive	Positive	Positive	Positive
Fampyra (Fampridine)	Negative	Negative	Negative	Negative
Incivek (Telaprevir)	Positive	None	Positive	None
Nplate (Romiplostim)	Negative	Positive	Negative	None
Nucala (Mepolizumab)	Positive	None	None	None
Ocrevus (ocrelizumab)	Positive	None	None	None
Praluent (Alirocumab)	Positive	None	None	None
Quinsair (Levofloxacin)	Positive	None	None	None
Revestive (Teduglutide)	Positive	None	Negative	None
Revolade (Eltrombopag olamine)	Negative	Positive	Negative	Negative
Samsca (Tolvaptan)	Negative	Negative	Negative	Negative

Drug	CDR recommendation	Provincial decisions		
		Ontario	British Columbia	Alberta
Soliris (Eculizumab)	Negative	None	Negative	Positive
Strengiq (Asfotase alfa)	Positive	None	None	None
Taltz (Ixezumab)	Positive	None	None	None
Technivie (Ombitasvir/paritaprevir/ritonavir)	Positive	None	Negative	None
Trulicity (Dulaglutide)	Positive	None	None	None
Uptravi (Selexipag)	Positive	None	None	None
Xgeva (Denosumab [Drug Plan Submission])	Positive	None	Positive	None
Aprilon (Doxycycline monohydrate)	Negative	None	Negative	Negative
Cimzia (Certolizumab pegol)	Negative	Positive	Positive	Negative
Constella (Linaclotide)	Negative	Negative	Negative	Negative
Duodopa (Levodopa/carbidopa)	Negative	Negative	Negative	Negative
Edarbyclor (Azilsartan medoxomil + chlorthalidone)	Negative	Negative	Negative	Negative
Effient (Prasugrel hydrochloride)	Negative	Positive	Positive	Negative
Elelyso (Taliglucerase alfa)	Negative	Negative	None	Negative
Inspra (Eplerenone)	Negative	Positive	Negative	Negative
Intuniv XR (Guanfacine hydrochloride)	Negative	None	Negative	Negative
Kazano (Alogliptin plus metformin)	Negative	Negative	Negative	Negative
Nesina (Alogliptin)	Negative	Negative	Negative	Negative
Nucynta CR (Tapentadol)	Negative	None	Negative	Negative
Orkambi (Lumacaftor/ivacaftor)	Negative	None	Negative	None
Relistor (Methylnaltrexone bromide)	Negative	Negative	Negative	Negative
Signifor (Pasireotide diaspertate)	Negative	Negative	Negative	Negative
Silkis (Calcitriol)	Negative	None	Negative	Negative
Zenhale (inhalation aerosol) (Mometasone furoate and formoterol)	Negative	Positive	Positive	Negative
Abilify (Aripiprazole)	Negative	Positive	Positive	Positive
Abilify (Aripiprazole)	Negative	Negative	Negative	Positive
Abilify Maintena (Aripiprazole)	Positive	Positive	Positive	Positive
Abstral (Fentanyl citrate)	Negative	Negative	Negative	Negative
Actemra (Tocilizumab)	Positive	Positive	Positive	Positive

Drug	CDR recommendation	Provincial decisions		
		Ontario	British Columbia	Alberta
Actikerall (Fluorouracil and Salicylic Acid)	Positive	None	None	None
Adcirca (Tadalafil)	Positive	Positive	Positive	None
Adlyxine (Lixisenatide)	Positive	None	None	None
Afinitor (Everolimus)	Negative	Positive	Negative	None
Aloxi (capsule) (Palonosetron hydrochloride)	Negative	None	Negative	Negative
Aloxi (injection) (Palonosetron hydrochloride)	Negative	None	Negative	Negative
Anoro Ellipta (Umeclidinium/vilanterol)	Positive	None	Positive	Positive
Apidra (Insulin glulisine)	Positive	Positive	Positive	Positive
Aptiom (Eslicarbazepine acetate)	Positive	Positive	Positive	Positive
Arnuity Ellipta (Fluticasone furoate)	Positive	None	Positive	Positive
ASMANEX (Mometasone furoate)	Positive	Positive	Positive	Positive
Azarga (Brimonidine and timolol maleate suspension)	Positive	Positive	Positive	Positive
Banzel (Rufinamide)	Positive	Positive	Positive	Positive
Basaglar (Insulin glargine)	Positive	Positive	None	Positive
Benlysta (Belimumab)	Negative	Negative	Negative	Negative
Botox (OnabotulinumtoxinA)	Positive	Positive	Positive	Positive
Brenzys (Etanercept)	Positive	Positive	Positive	Positive
Breo Ellipta (Fluticasone furoate/vilanterol)	Positive	None	Positive	Positive
Brilinta (Ticagrelor)	Negative	None	Positive	Positive
Brivlera (Brivaracetam)	Positive	None	Negative	None
Byetta (Exenatide)	Negative	Negative	Negative	Negative
Bystolic (Nebivolol)	Negative	Negative	Negative	None
Cayston (Aztreonam for inhalation solution)	Positive	None	Positive	Positive
Cimzia (Certolizumab pegol)	Positive	None	Positive	Positive
COMPLERA (Emtricitabine/rilpivirine/tenofovir disoproxil fumarate)	Positive	Positive	None	None
Cosentyx (Secukinumab)	Positive	None	None	None
Cosentyx (Secukinumab)	Positive	None	None	None
Daxas (Roflumilast)	Negative	None	Negative	Negative

Drug	CDR recommendation	Provincial decisions		
		Ontario	British Columbia	Alberta
Descovy (Emtricitabine/tenofovir alafenamide)	Positive	None	None	None
Dymista (Azelastine HCl and fluticasone propionate)	Negative	Negative	Negative	Negative
Dysport Therapeutic (abobotulinumtoxinA)	Positive	None	None	None
Edarbi (Azilsartan medoxomil)	Negative	None	Negative	Negative
Edurant (Rilpivirine)	Positive	Positive	None	None
Egrifta (Tesamorelin)	Negative	None	Negative	Negative
Entyvio (Vedolizumab)	Positive	Positive	Positive	Positive
Entyvio (Vedolizumab)	Positive	Positive	Positive	Positive
Erelzi (Etanercept)	Positive	None	Positive	None
Esbriet (Pirfenidone)	Negative	Positive	Negative	Negative
Eylea (Aflibercept)	Positive	Positive	None	Positive
Fentora (Fentanyl buccal)	Negative	None	Negative	Negative
Ferriprox (Deferiprone)	Positive	None	Positive	Positive
Finacea (Azelaic acid)	Positive	Positive	Positive	Positive
Forxiga (Dapagliflozin)	Positive	None	None	Negative
Fosavance 70/5600 (Alendronate sodium/cholecalciferol)	Positive	None	Positive	Positive
Gelnique (Oxybutynin Chloride Gel)	Negative	Negative	Negative	Negative
Genotropin (Somatropin)	Positive	Positive	Negative	Positive
Genotropin (Somatropin)	Positive	Positive	Positive	None
Genotropin (Somatropin)	Positive	None	Negative	Positive
Genvoya (Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)	Positive	Positive	None	None
Gilenya (Fingolimod)	Positive	Positive	Positive	Positive
Glatect (Glatiramer acetate)	Positive	None	None	None
Grastofil (Filgrastim)	Positive	None	Positive	Positive
Hemangirol (Propranolol oral solution)	Positive	None	None	None
Ilaris (Canakinumab)	Negative	None	Negative	Negative
Incruse Ellipta (Umeclidinium)	Positive	Positive	Positive	Positive
Inflixtra (Infliximab)	Positive	Positive	Positive	Positive
Inspiolto Respimat (Tiotropium/olodaterol)	Positive	None	Positive	Positive

Drug	CDR recommendation	Provincial decisions		
		Ontario	British Columbia	Alberta
Invega Sustenna (Paliperidone palmitate)	Negative	Positive	Positive	Positive
Invokamet (Canagliflozin and metformin hydrochloride)	Positive	None	None	Negative
Izba (Travoprost ophthalmic solution)	Positive	None	None	None
Janumet (Sitagliptin phosphate monohydrate/metformin hydrochloride)	Positive	None	Positive	Positive
Jentaduetto (Linagliptin-metformin)	Positive	Positive	Positive	Positive
Jurnista (Hydromorphone hydrochloride)	Negative	Negative	Positive	None
Juxtapid (Lomitapide)	Negative	Negative	Negative	Negative
Kevzara (sarilumab)	Positive	None	Negative	None
Komboglyze (Saxagliptin + metformin)	Positive	None	Positive	Positive
Kuvan (Sapropterin dihydrochloride)	Negative	Positive	Negative	Negative
Latuda (Lurasidone)	Negative	Positive	Negative	Negative
Lodalis (Colesevelam hydrochloride)	Negative	Positive	Negative	Positive
Lotemax (Loteprednol etabonate)	Negative	Negative	Negative	None
Lucentis (Ranibizumab)	Positive	Positive	None	Positive
Lucentis (Ranibizumab)	Positive	Positive	None	None
Lucentis (Ranibizumab injection)	Positive	Positive	None	Negative
Mictoryl (Propiverine hydrochloride)	Positive	None	None	None
Mifegymiso (Mifepristone and misoprostol)	Positive	None	Positive	None
Mozobil (Plerixafor)	Negative	Positive	None	Positive
Multaq (Dronedarone hydrochloride)	Negative	Negative	Positive	None
Myrbetriq (Mirabegron)	Positive	Positive	Negative	Positive
Naglazyme (Galsulfase [Drug Plan Submission])	Positive	None	None	None
Neupro (Rotigotine)	Negative	Negative	Negative	Negative
Ocaliva (Obeticholic acid)	Positive	None	None	None
Odefsey (Emtricitabine/rilpivirine/tenofovir alafenamide)	Positive	None	None	None
Olmotec (Olmesartan medoxomil)	Positive	None	Positive	Positive
Olmotec Plus (Olmesartan medoxomil + hydrochlorothiazide)	Positive	Positive	Positive	Positive
Onbrez (Indacaterol)	Positive	None	Positive	Positive
Onglyza (Saxagliptin)	Negative	Positive	None	Positive

Drug	CDR recommendation	Provincial decisions		
		Ontario	British Columbia	Alberta
Opsumit (Macitentan)	Positive	Negative	Negative	None
Oralair (Grass pollen allergen extract)	Positive	None	Negative	None
Otezla (Apremilast)	Negative	Negative	Negative	Negative
Ozurdex (Dexamethasone intravitreal implant)	Negative	Negative	Negative	Negative
Pheburane (Sodium phenylbutyrate)	Positive	None	Positive	None
Picato (Ingenol mebutate)	Negative	Negative	Negative	Negative
Plegridy (Peginterferon beta-1a)	Positive	Positive	Negative	Positive
Pradaxa (Dabigatran etexilate)	Negative	Negative	Negative	Negative
Pristiq (Desvenlafaxine succinate)	Negative	Negative	Negative	Negative
Prolia (Denosumab)	Positive	Positive	Positive	Positive
Prolia (Denosumab [Drug Plan Submission])	Positive	None	Positive	Positive
RAPAFLO (Silodosin)	Negative	Positive	Negative	Negative
Ravicti (Glycerol phenylbutyrate)	Positive	None	Positive	None
Rebif (Interferon beta-1a)	Negative	Positive	Negative	Positive
Resotran (Prucalopride)	Negative	Negative	Negative	Negative
Restasis ophthalmic emulsion (Cyclosporine)	Negative	None	Negative	Negative
Rexulti (Brexpirazole)	Positive	None	None	None
Rosiver (Ivermectin)	Positive	None	Negative	Negative
Saphris (Asenapine)	Negative	Positive	Negative	Negative
Saphris (Asenapine)	Positive	Positive	Positive	Positive
Seebri (Glycopyrronium bromide)	Positive	Positive	Positive	Positive
Simponi (Golimumab)	Positive	Positive	Positive	Positive
Simponi (Golimumab)	Positive	Positive	Positive	Positive
Simponi (Golimumab)	Positive	None	Positive	Positive
Spiriva Respimat (Tiotropium bromide)	Positive	Positive	Positive	Positive
Stelara (Ustekinumab)	Positive	Positive	Positive	Positive
Stribild (Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)	Positive	Positive	None	None
Sublinox (Zolpidem tartrate)	Negative	None	Negative	Negative
Synjardy (Empagliflozin and metformin)	Positive	None	None	None

Drug	CDR recommendation	Provincial decisions		
		Ontario	British Columbia	Alberta
Tocino (Alitreinoin)	Positive	Positive	Positive	Negative
Toviaz (Fesoterodine fumarate)	Positive	Positive	Negative	Positive
Trajenta (Linagliptin)	Positive	Positive	Positive	Positive
Tresiba (Insulin degludec)	Positive	None	None	None
Tudorza Genuair (Acclidinium bromide)	Positive	Positive	Positive	Positive
Twynsta (Telmisartan/Amlodipine)	Positive	None	Positive	Positive
Uloric (Febuxostat)	Positive	Positive	Positive	Positive
Ultibro Breezhaler (Indacaterol/glycopyrronium)	Positive	Positive	Positive	Positive
Viacoram (Perindopril arginine/amlodipine)	Positive	None	Negative	None
Victoza (Liraglutide)	Negative	Negative	Negative	Negative
Vimizim (Elosulfase alfa)	Negative	None	Negative	Negative
Vimpat (Lacosamide)	Positive	Positive	Positive	Positive
Visanne (Dienogest)	Positive	Positive	Positive	Positive
VPRIV (Velaglycerase alfa)	Positive	Positive	Negative	None
Vyvanse (Lisdexamfetamine dimesylate)	Negative	None	Negative	Positive
Xarelto (Rivaroxaban)	Positive	None	Positive	Positive
Xeljanz (Tofacitinib)	Positive	Positive	Positive	Positive
Xeomin (Clostridium botulinum neurotoxin type A, free from complexing proteins)	Positive	Positive	Positive	Positive
Xeomin (Clostridium botulinum neurotoxin type A, free from complexing proteins)	Positive	Positive	Positive	Positive
Xeomin (Clostridium botulinum neurotoxin type A, free from complexing proteins)	Negative	Negative	Positive	Positive
Xgeva (Denosumab [Drug Plan Submission])	Positive	None	Positive	None
Xiaflex (Collagenase clostridium histolyticum)	Positive	None	Negative	Negative
XigDuo (Dapagliflozin/metformin hydrochloride)	Positive	Positive	None	Positive
Eliquis (Apixaban)	Positive	Positive	Positive	Positive
Entresto (Sacubitril/valsartan)	Positive	Positive	None	Positive
Lancora (Ivabradine)	Positive	None	None	None

Drug	CDR recommendation	Provincial decisions		
		Ontario	British Columbia	Alberta
Lemtrada (Alemtuzumab)	Positive	None	None	Positive
Lixiana NVAF (Edoxaban)	Positive	None	None	None
Repatha (Evolocumab)	Positive	None	None	None
Zaxine (Rifaximin)	Positive	Positive	None	Positive
Zepatier (Elbasvir/grazoprevir)	Positive	None	Positive	Positive
Zinbryta (Daclizumab beta)	Positive	None	None	None

Note: When drugs were submitted for multiple indications, each indication was treated as a separate entry.

An Exploratory Analysis of Predictors of Concordance between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta

Analyse exploratoire des prédicteurs de la concordance entre les recommandations de remboursement du Programme commun d'évaluation des médicaments et les décisions subséquentes de l'Ontario, de la Colombie-Britannique et de l'Alberta

MICHAEL J. ZORATTI, FENG XIE, KRISTIAN THORLUND, NICOLA ALLEN AND MITCHELL LEVINE

Appendix 2: Predictor definitions with examples from CDR recommendation rationales

Predictor	Level	Definition	Example, with emphasis on predictor-relevant text
Clinical outcomes vs. placebo	Positive	Superior clinical outcomes compared to placebo	"In Studies 3082 and 3083, reslizumab was associated with a statistically significant reduction in the rate of clinically significant asthma exacerbations compared with placebo at 52 weeks in patients currently on medium- to high-dose ICSs with or without additional asthma controller(s) and an elevated blood eosinophil level (i.e., ≥ 400 cells/ μ L)." Reslizumab for Asthma, eosinophilic March 22, 2017
	Negative	Inferior clinical outcomes compared to placebo	"In the eight double-blind randomized controlled trials (RCTs) reviewed by CDR, asenapine failed to consistently demonstrate superiority in the five placebo-controlled trials. " Asenapine for Schizophrenia June 14, 2012
Clinical outcomes vs. active comparator	Positive	Comparable or non-inferior, or superior clinical outcomes compared to an active comparator	"One open-label, head-to-head randomized controlled trial (RCT) (ENCORE; $N = 159$) demonstrated that eliglustat is non-inferior to imiglucerase with respect to achieving disease stability (a composite of hematologic levels and organ volumes) over 52 weeks of treatment among ERT-experienced patients with well-controlled type I Gaucher disease." Eliglustat for Gaucher disease July 26, 2017
	Negative	Inferior clinical outcomes compared to an active comparator	"Oral palonosetron failed to demonstrate non-inferiority against intravenous (IV) palonosetron for delayed chemotherapy-induced nausea and vomiting." Palonosetron hydrochloride for Nausea and vomiting (chemotherapy-induced) prevention April 24, 2013

Predictor	Level	Definition	Example, with emphasis on predictor-relevant text
Cost	Positive	Similarly or less costly than currently available treatment options	"At the submitted price (\$x.xx per 200 mg, 400 mg, 600 mg, or 800 mg tablet), treatment with eslicarbazepine acetate has a lower daily cost than treatment with some other adjunctive AEDs. " Eslicarbazepine acetate for Epilepsy, partial-onset seizures April 15, 2016
	Negative	More costly than currently available treatment options	"The cost of methylalthretone is [redacted] per dose, which is greater than that of oral laxatives, suppositories or sodium phosphate enemas. " Methylalthretone bromide for Constipation, opioid-induced January 28, 2009
Safety or tolerability	Positive	No safety or tolerability concerns	"Evidence from two phase 3, double-blind, randomized placebo-controlled trials supports the safety and efficacy of mepolizumab." Mepolizumab for Asthma, severe eosinophilic June 16, 2016
	Negative	Safety or tolerability concerns are raised (either poor safety profile or unknown effects)	"There is insufficient evidence regarding the long-term safety of tesamorelin therapy, which is of concern because tesamorelin may be used for extended periods due to the re-accumulation of VAT that occurs upon cessation of tesamorelin therapy." Tesamorelin for Lipodystrophy, HIV-infected patients August 24, 2016
Patient subgroup-specific evidence, such as population subgroups or previous treatment status	Positive	Sufficient evidence is presented to address important patient subgroups	"High rates of sustained virologic response at 12 weeks (SVR12) were observed across all genotypes and among treatment-naïve and previously treated patients in the four trials reviewed." Sofosbuvir/velpatasvir for Hepatitis C, chronic October 26, 2016
	Negative	Insufficient evidence presented on the effects of the treatment in important patient subgroups	"There are no RCTs comparing the incidence of anticholinergic adverse effects (such as cognitive and neurological) between oxybutynin chloride gel and other oxybutynin products, particularly in the elderly. " Oxybutynin Chloride Gel for Bladder, overactive May 24, 2012
Incremental cost-effectiveness ratio	Positive	The incremental cost-effectiveness ratio (ICER) is low or favourable	"Results from the manufacturer's cost utility analysis suggest that apixaban is cost-effective compared with enoxaparin , resulting in lower costs and similar quality-adjusted life-years (QALYs) in both knee and hip replacement surgery, for treatment durations of 14 days and 35 days, respectively." Apixaban for Thromboembolic events, (venous) prevention June 14, 2012
	Negative	The ICER is high or unfavourable	"The CADTH Common Drug Review (CDR) base-case incremental cost-utility ratios (ICURs) were \$278,000 and \$1,500,000 compared with a sulfonylurea and a dipeptidyl peptidase-4 (DPP-4) inhibitor." Dulaglutide for Diabetes mellitus, Type 2 June 16, 2016

Predictor	Level	Definition	Example, with emphasis on predictor-relevant text
Consistency/certainty in clinical evidence	Positive	Consistent and certain clinical evidence across trials	No examples
	Negative	Inconsistent or uncertain clinical evidence across trials	"The Committee considered the comparative efficacy of prasugrel and clopidogrel to be uncertain due to the design of the TRITON-TIMI 38 study." Prasugrel hydrochloride for Acute Coronary Syndrome (ACS) February 16, 2011
Consistency/certainty in economic evidence	Positive	Consistent and certain economic evidence	No examples
	Negative	Inconsistent or uncertain economic evidence	"However, CDR reanalyses demonstrated that there was substantial variability within the pharmacoeconomic evaluation , ranging from alemtuzumab dominating Rebif to \$91,000 per quality-adjusted life-year (QALY) for alemtuzumab compared with Rebif." Alemtuzumab for Multiple Sclerosis, relapsing-remitting June 18, 2015
Quality of methods used in supporting clinical research	Positive	There are no methodological methods in the clinical evidence (not the approach to evidence synthesis)	No examples
	Negative	There are methodological methods in the clinical evidence (not the approach to evidence synthesis)	"The two trials were limited by a lack of double-blinding in the evaluation of subjective outcomes and data on quality of life were not reported." Calcitriol for Psoriasis, mild to moderate plaque September 22, 2010
Clinical outcomes from non-comparative trials	Positive	Favourable clinical outcomes coming from a non-comparative trial	"Two additional RCTs and one single-group prospective study also provided evidence that mifepristone and misoprostol are associated with successful complete abortion (95% to 97% success rates)." Mifepristone and misoprostol for Medical termination of pregnancy April 18, 2017
	Negative	Unfavourable clinical outcomes coming from a non-comparative trial	"CDEC considered the clinical benefit of pasireotide for the treatment of Cushing disease to be uncertain, due to limitations in the design of the single uncontrolled trial (B2305; N = 162), the absence of a clear rationale for the response rate threshold (i.e., 15% of patients), the failure to achieve the primary end point with the 0.6 mg twice daily recommended dose of pasireotide, and the high proportion of participants who discontinued treatment within 12 months (60%)." Pasireotide diaspertate for Cushing's disease February 24, 2015

Predictor	Level	Definition	Example, with emphasis on predictor-relevant text
Evidence synthesis methods, only citing use of a network meta-analysis	Positive	A network meta-analysis was used and this evidence synthesis approach is well suited to addressing this clinical question	"A manufacturer-submitted network meta-analysis (NMA) suggested that TIO/OLO has similar efficacy compared with other LAMA/LABA combination therapies for improving lung function, health-related quality of life, dyspnea, and COPD exacerbations." Tiotropium/olodaterol for Chronic Obstructive Pulmonary Disease (COPD) December 17, 2015
	Negative	A network meta-analysis was used, and there are limitations with this method	"Although five indirect comparisons reviewed by the CADTH Common Drug Review (CDR) included comparisons of vedolizumab against other biologic treatments for CD, limitations associated with these comparisons precluded any definitive conclusions regarding the comparative efficacy and safety of vedolizumab compared with TNF alpha antagonists." Vedolizumab for Crohn's disease October 31, 2016
Replacement vs. currently available treatments	Positive	The treatment under review has been demonstrated as an appropriate/sufficient replacement for currently available treatment options	No examples
	Negative	The treatment under review has not been demonstrated as an appropriate/sufficient replacement for currently available treatment options	"The Committee considered that the quality of the certolizumab pegol randomized controlled trials was limited and that other therapeutic options are available. " Certolizumab pegol for Arthritis, rheumatoid May 27, 2010
Evidence synthesis methods, other than a network meta-analysis	Positive	No methodological limitations have been identified with the evidence synthesis approach used in this submission	No examples
	Negative	There are methodological limitations to the evidence synthesis approach in this submission	No examples

An Exploratory Analysis of Predictors of Concordance between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta

Analyse exploratoire des prédicteurs de la concordance entre les recommandations de remboursement du Programme commun d'évaluation des médicaments et les décisions subséquentes de l'Ontario, de la Colombie-Britannique et de l'Alberta

MICHAEL J. ZORATTI, FENG XIE, KRISTIAN THORLUND, NICOLA ALLEN AND MITCHELL LEVINE

Appendix 3: Predictors coded based on review of CDR rationales

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Abilify (Aripiprazole)	Schizophrenia	Negative	NR	NR	NR	–	NR	NR	+	NR	NR	NR	NR	NR	NR
Abilify (Aripiprazole)	Depression, major depressive disorder (MDD)	Negative	NR	NR	NR	NR	NR	+	NR	–	NR	NR	NR	NR	NR
Abilify Maintena (Aripiprazole)	Schizophrenia	Positive	NR	NR	NR	+	NR	+	+	NR	NR	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Abstral (Fentanyl citrate)	Pain, cancer (breakthrough)	Negative	NR	NR	NR	–	NR	NR	NR	NR	NR	NR	NR	NR	NR
Actemra (Tocilizumab)	Arthritis, rheumatoid	Positive	NR	NR	NR	NR	NR	+	NR	–	NR	NR	NR	NR	NR
Actikerall (Fluorouracil and Salicylic acid)	Hyperkeratotic actinic keratosis	Positive	NR	NR	+	+	NR	+	NR	–	NR	–	NR	NR	NR
Adcirca (Tadalafil)	Pulmonary arterial hypertension	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Adempas (Riociguat)	Pulmonary hypertension, chronic thromboembolic	Positive	NR	NR	NR	–	NR	+	NR	NR	–	NR	NR	NR	NR
Adlyxine (Lixisenatide)	Diabetes mellitus, type 2	Positive	NR	NR	NR	NR	NR	+	+	NR	NR	NR	NR	NR	NR
Afinitor (Everolimus)	Renal angiomyolipoma associated with tuberous sclerosis complex	Negative	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Aloxi (capsule) (Palonosetron hydrochloride)	Nausea and vomiting (chemotherapy-induced) prevention	Negative	NR	NR	NR	NR	NR	NR	–	NR	NR	NR	NR	NR	NR
Aloxi (injection) (Palonosetron hydrochloride)	Nausea and vomiting (chemotherapy-induced) prevention	Negative	NR	NR	NR	–	NR	NR	NR	NR	NR	–	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Anoro Ellipta (Umeclidinium/vilanterol)	Chronic obstructive pulmonary disease	Positive	NR	NR	NR	+	NR	+	+	NR	NR	NR	NR	NR	NR
Apidra (Insulin glulisine)	Diabetes mellitus (types 1 and 2)	Positive	NR	NR	+	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Aprilon (Doxycycline monohydrate)	Rosacea treatment	Negative	NR	NR	NR	NR	NR	NR	NR	–	NR	NR	–	NR	NR
Aptiom (Eslicarbazepine acetate)	Epilepsy, partial-onset seizures	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Arnuity Ellipta (Fluticasone furoate)	Asthma	Positive	NR	NR	NR	+	NR	+	+	NR	NR	NR	NR	NR	NR
ASMANEX (Mometasone furoate)	Asthma, (bronchial) prophylactic management of steroid responsive	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Azarga (Brinzolamide and timolol maleate suspension)	Glaucoma and ocular hypertension	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Banzel (Rufinamide)	Lennox–Gastaut syndrome; adjunctive treatment of seizures	Positive	NR	NR	NR	–	NR	+	NR	NR	NR	NR	NR	NR	NR
Basaglar (Insulin glargine)	Diabetes mellitus, types 1 and 2	Positive	NR	NR	+	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Benlysta (Belimumab)	Systemic lupus erythematosus	Negative	NR	NR	NR	NR	NR	–	NR	–	–	–	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Botox (OnabotulinumtoxinA)	Neurogenic detrusor overactivity	Positive	NR	NR	NR	NR	NR	+	NR	NR	+	-	NR	NR	NR
Brenzys (Etanercept)	Rheumatoid arthritis, ankylosing spondylitis	Positive	NR	NR	+	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Breo Ellipta (Fluticasone furoate/vilanterol)	Chronic obstructive pulmonary disease (COPD)	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Brilinta (Ticagrelor)	Thrombotic events in acute coronary syndromes, prevention	Negative	-	NR	NR	-	NR	NR	-	NR	NR	-	NR	NR	NR
Brivlera (Brivaracetam)	Epilepsy, partial-onset seizures	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Byetta (Exenatide)	Diabetes mellitus, type 2	Negative	NR	NR	NR	-	NR	NR	+	-	NR	NR	NR	NR	NR
Bystolic (Nebivolol)	Hypertension, essential	Negative	NR	NR	NR	-	NR	NR	-	NR	NR	NR	NR	NR	NR
Cayston (Aztreonam for inhalation solution)	Cystic fibrosis (CF) with chronic pulmonary <i>Pseudomonas aeruginosa</i> infections	Positive	NR	NR	NR	-	NR	NR	+	NR	NR	NR	NR	NR	NR
Cerdelga (Eliglustat)	Gaucher disease	Positive	NR	NR	NR	-	NR	+	+	NR	-	NR	NR	NR	NR
Cimzia (Certolizumab pegol)	Arthritis, rheumatoid	Negative	NR	-	NR	NR	NR	NR	NR	NR	NR	NR	-	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Cimzia (Certolizumab pegol)	Ankylosing spondylitis	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Cinqair (Reslizumab)	Asthma, eosinophilic	Positive	NR	NR	NR	-	NR	+	NR	NR	-	NR	NR	-	NR
COMPLERA (Emtricitabine/ilpivirine/tenofovir disoproxil fumarate)	HIV-1 infection in antiretroviral treatment-naïve adults	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Constella (Linaclotide)	Irritable bowel syndrome with constipation	Negative	NR	NR	NR	NR	NR	+	NR	-	NR	NR	-	NR	NR
Cosentyx (Secukinumab)	Arthritis, psoriatic	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Cosentyx (Secukinumab)	Ankylosing spondylitis	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Daxas (Roflumilast)	COPD	Negative	NR	NR	NR	NR	NR	-	NR	NR	NR	NR	NR	NR	NR
Descovy (Emtricitabine/tenofovir alafenamide)	HIV-1 infection	Positive	+	NR	NR	+	+	NR	+	NR	NR	NR	NR	NR	NR
Diacomit (Stiripentol)	Dravet syndrome	Positive	NR	NR	NR	-	NR	+	NR	NR	-	NR	NR	NR	NR
Dificid (Fidaxomicin)	<i>Clostridium difficile</i> infection	Negative	NR	NR	NR	-	NR	NR	+	NR	-	-	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Duodopa (Levodopa/carbidopa)	Parkinson's disease	Negative	NR	NR	NR	NR	NR	NR	NR	NR	–	NR	–	NR	NR
Dymista (Azelastine HCl and fluticasone propionate)	Seasonal allergic rhinitis	Negative	NR	NR	NR	NR	NR	+	–	–	NR	NR	NR	NR	NR
Dysport Therapeutic (AbobotulinumtoxinA)	Cervical dystonia	Positive	NR	NR	NR	–	NR	+	NR	NR	NR	NR	NR	NR	NR
Edarbi (Azilsartan medoxomil)	Hypertension, essential	Negative	NR	NR	NR	–	NR	NR	NR	NR	NR	NR	NR	NR	NR
Edarbyclor (Azilsartan medoxomil + chlorthalidone)	Hypertension, essential	Negative	NR	NR	NR	NR	NR	NR	NR	–	NR	NR	–	NR	NR
Edurant (Rilpivirine)	HIV (treatment-naïve adult)	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Effient (Prasugrel hydrochloride)	Acute coronary syndrome (ACS)	Negative	NR	NR	NR	NR	NR	NR	+	–	NR	NR	–	NR	NR
Egrifta (Tasamorelin)	Lipodystrophy, HIV-infected patients	Negative	NR	NR	–	NR	NR	+	NR	–	NR	NR	NR	NR	NR
Elelyso (Talgiferase alfa)	Gaucher's disease	Negative	NR	NR	NR	NR	+	NR	NR	–	NR	NR	–	–	NR
Eliquis (Apixaban)	Thromboembolic events, (venous) prevention	Positive	NR	NR	+	NR	NR	NR	+	NR	+	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Entresto (Sacubitril/valsartan)	Heart failure, New York Heart Association class II or III	Positive	NR	NR	NR	NR	NR	NR	+	NR	+	NR	NR	NR	NR
Entyvio (Vedolizumab)	Ulcerative colitis	Positive	+	NR	NR	–	NR	+	NR	NR	–	–	NR	–	NR
Entyvio (Vedolizumab)	Crohn's disease	Positive	+	NR	NR	–	NR	+	NR	NR	NR	NR	NR	–	NR
Epclusa (Sofosbuvir/velpatasvir)	Hepatitis C, chronic	Positive	+	NR	NR	–	NR	+	+	NR	–	–	NR	NR	NR
Erelzi (Etanercept)	Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis	Positive	NR	NR	+	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Esbriet (Pirfenidone)	Pulmonary fibrosis (idiopathic, mild to moderate)	Negative	NR	NR	NR	NR	NR	–	NR	–	NR	NR	NR	NR	NR
Eylea (Aflibercept)	Macular degeneration, age-related	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Fampyra (Fampridine)	Multiple sclerosis, improve walking disability	Negative	NR	NR	NR	NR	NR	+	NR	NR	–	–	NR	NR	NR
Fentora (Fentanyl buccal)	Pain (breakthrough), cancer (adults)	Negative	–	–	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Ferriprox (Deferiprone)	Transfusional iron overload	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Finacea (Azelaic acid)	Rosacea	Positive	NR	NR	NR	NR	NR	NR	+	NR	NR	NR	NR	NR	NR
Forxiga (Dapagliflozin)	Diabetes mellitus (type 2)	Positive	NR	NR	NR	NR	NR	+	+	NR	NR	NR	NR	NR	NR
Fosavance 70/5600 (Alendronate sodium/cholecalciferol)	Osteoporosis	Positive	NR	NR	NR	+	NR	NR	-	NR	NR	NR	NR	NR	NR
Gelnique (Oxybutynin Chloride Gel)	Bladder, overactive	Negative	-	NR	NR	NR	NR	NR	NR	-	NR	NR	NR	NR	NR
Genotropin (Somatropin)	Growth hormone deficiency, adult	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Genotropin (Somatropin)	Growth hormone deficiency, pediatric	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Genotropin (Somatropin)	Turner syndrome	Positive	NR	NR	NR	+	+	NR	NR	NR	NR	NR	NR	NR	NR
Genvoya (Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)	HIV-1 infection	Positive	+	NR	NR	+	+	NR	+	NR	NR	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Gilenya (Fingolimod)	Multiple sclerosis	Positive	NR	NR	NR	–	NR	NR	+	NR	NR	NR	NR	NR	NR
Glatect (Glatiramer acetate)	Multiple sclerosis, relapsing-remitting	Positive	NR	NR	+	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Grastofil (Filgrastim)	Prevention or treatment of neutropenia in various indications	Positive	NR	NR	NR	+	+	NR	+	NR	NR	NR	NR	NR	NR
Hemangirol (Propranolol oral solution)	Infantile hemangioma	Positive	+	NR	NR	–	NR	+	NR	NR	NR	NR	NR	NR	NR
Ilaris (Canakinumab)	Cryopyrin-associated periodic syndrome	Negative	NR	NR	NR	NR	NR	+	NR	–	NR	NR	NR	NR	NR
Incivek (Telaprevir)	Hepatitis C infection (genotype 1), chronic	Positive	+	NR	NR	–	NR	+	NR	NR	–	–	NR	NR	NR
Incruse Ellipta (Umeclidinium)	COPD	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Inflectra (Infliximab)	Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Inspiolto Respimat (Tiotropium/olodaterol)	COPD	Positive	NR	NR	NR	+	NR	+	+	NR	NR	NR	NR	+	NR
Inspira (Eplerenone)	Post-myocardial infarction	Negative	NR	NR	NR	NR	NR	NR	–	NR	NR	–	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Intuniv XR (Guanfacine hydrochloride)	Attention-deficit hyperactivity disorder (ADHD)	Negative	NR	NR	NR	NR	NR	NR	–	NR	NR	NR	–	NR	NR
Invega Sustenna (Paliperidone palmitate)	Schizophrenia	Negative	NR	NR	NR	–	NR	NR	+	NR	NR	NR	NR	NR	NR
Invokamet (Canagliflozin and metformin hydrochloride)	Diabetes mellitus, type 2	Positive	NR	NR	NR	–	NR	+	+	NR	NR	NR	NR	NR	NR
Izba (Travoprost ophthalmic solution)	Open-angle glaucoma	Positive	NR	NR	+	–	NR	NR	+	NR	NR	NR	NR	NR	NR
Janumet (Sitagliptin phosphate monohydrate/metformin hydrochloride)	Diabetes mellitus (type 2)	Positive	NR	NR	NR	+	NR	NR	NR	NR	NR	NR	NR	NR	NR
Jentadueto (Linagliptin-metformin)	Diabetes mellitus (type 2)	Positive	NR	NR	NR	+	NR	NR	NR	NR	NR	NR	NR	NR	NR
Jurnista (Hydromorphone hydrochloride)	Pain, chronic (moderate to severe)	Negative	NR	NR	NR	–	NR	NR	–	NR	NR	NR	NR	NR	NR
Juxtapid (Lomitapide)	Hypercholesterolemia, homozygous familial	Negative	NR	NR	–	NR	+	NR	NR	–	NR	NR	–	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Kazano (Alogliptin plus metformin)	Diabetes mellitus (type 2)	Negative	NR	NR	NR	–	NR	NR	NR	–	NR	NR	–	NR	NR
Kevzara (sarilumab)	Arthritis, rheumatoid	Positive	NR	NR	NR	–	NR	+	+	NR	NR	NR	NR	NR	NR
Komboglyze (Saxagliptin + metformin)	Diabetes mellitus, type 2	Positive	NR	NR	NR	+	NR	NR	NR	NR	NR	NR	NR	NR	NR
Kuvan (Sapropterin dihydrochloride)	Phenylketonuria	Negative	–	NR	NR	NR	NR	NR	NR	NR	–	NR	NR	NR	NR
Lancora (lvabradine)	Heart failure, NYHA class II or III	Positive	+	NR	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR
Latuda (Lurasidone)	Schizophrenia	Negative	NR	NR	NR	–	NR	NR	–	–	NR	NR	NR	NR	NR
Lemtrada (Alemtuzumab)	Multiple sclerosis, relapsing-remitting	Positive	NR	NR	NR	NR	NR	NR	+	NR	NR	–	NR	NR	NR
Lixiana NVAf (Edoxaban)	Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism	Positive	+	NR	NR	–	NR	NR	+	NR	+	–	NR	NR	NR
Lodalis (Colesevelam hydrochloride)	Hypercholesterolemia	Negative	NR	NR	NR	–	NR	NR	NR	–	NR	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Lotemax (Loteprednol etabonate)	Post-operative inflammation following cataract surgery	Negative	NR	NR	NR	–	NR	NR	NR	–	NR	NR	NR	NR	NR
Lucentis (Ranibizumab injection)	Macular edema, secondary to retinal vein occlusion	Positive	NR	NR	NR	NR	NR	+	NR	NR	NR	–	NR	NR	NR
Lucentis (Ranibizumab)	Macular edema, diabetic	Positive	NR	NR	NR	NR	NR	+	NR	NR	NR	–	NR	NR	NR
Lucentis (Ranibizumab)	Choroidal neovascularization, myopic	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	–	NR	NR	NR
Mictoryl (Propiverine hydrochloride)	Overactive bladder	Positive	NR	NR	NR	–	NR	+	+	NR	NR	NR	NR	NR	NR
Mifegymiso (Mifepristone and misoprostol)	Medical termination of pregnancy	Positive	NR	NR	+	NR	+	NR	+	NR	NR	NR	–	NR	NR
Mozobil (Plerixafor)	Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma	Negative	–	NR	NR	NR	NR	NR	NR	–	NR	–	NR	NR	NR
Multaq (Dronedaron hydrochloride)	Atrial fibrillation	Negative	NR	NR	NR	–	NR	+	–	–	NR	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Myrbetriq (Mirabegron)	Bladder, overactive	Positive	NR	NR	+	+	NR	+	+	NR	NR	NR	NR	+	NR
Naglazyme (Galsulfase [Drug Plan Submission])	Mucopolysaccharidosis VI	Positive	NR	NR	NR	-	NR	+	NR	NR	NR	NR	NR	NR	NR
Nesina (Alogliptin)	Diabetes mellitus (type 2)	Negative	NR	NR	NR	-	NR	NR	NR	-	NR	NR	-	NR	NR
Neupro (Rotigotine)	Parkinson's disease	Negative	NR	NR	NR	-	NR	NR	-	-	NR	NR	NR	NR	NR
Nplate (Romiplostim)	Chronic immune (idiopathic) thrombocytopenic purpura	Negative	NR	NR	NR	NR	NR	NR	NR	-	-	NR	NR	NR	NR
Nucala (Mepolizumab)	Asthma, severe eosinophilic	Positive	NR	NR	+	-	NR	+	NR	NR	-	NR	NR	NR	NR
Nucynta CR (Tapentadol)	Pain, moderate to moderately severe	Negative	NR	NR	NR	NR	NR	NR	-	-	NR	NR	NR	NR	NR
Ocaliva (Obeticholic acid)	Primary biliary cholangitis	Positive	NR	NR	NR	-	NR	+	NR	-	-	-	NR	NR	NR
Ocrevus (Ocrelizumab)	Multiple sclerosis, relapsing	Positive	NR	NR	NR	-	NR	NR	+	NR	-	NR	NR	NR	NR
Odefsey (Emtricitabine/rilpivirine/tenofovir alafenamide)	HIV-1 infection	Positive	NR	NR	+	+	NR	NR	+	NR	NR	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Olmotec (Olmesartan medoxomil)	Hypertension	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Olmotec Plus (Olmesartan medoxomil + hydrochlorothiazide)	Hypertension	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Onbrez (Indacaterol)	COPD, maintenance bronchodilator treatment	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Onglyza (Saxagliptin)	Diabetes mellitus (type 2)	Negative	–	NR	NR	–	NR	NR	NR	NR	NR	NR	NR	NR	NR
Opsumit (Macitentan)	Pulmonary arterial hypertension	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Oralair (Grass pollen allergen extract)	Allergic rhinitis (grass pollen)	Positive	NR	NR	NR	–	NR	+	NR	NR	NR	NR	NR	NR	NR
Orkambi (Lumacaftor/ivacaftor)	Cystic fibrosis, F508del CFTR mutation	Negative	NR	NR	NR	NR	NR	+	NR	–	NR	NR	–	NR	NR
Otezla (Apremilast)	Psoriasis, moderate to severe plaque	Negative	–	NR	NR	NR	NR	+	NR	–	NR	NR	NR	–	NR
Ozurdex (Dexamethasone intravitreal implant)	Macular edema following central retinal vein occlusion	Negative	NR	NR	NR	NR	NR	–	NR	–	NR	–	NR	NR	NR
Pheburane (Sodium phenylbutyrate)	Urea cycle disorders	Positive	NR	NR	NR	+	+	NR	NR	NR	NR	–	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Picato (Ingenuol mebutate)	Keratosis, actinic	Negative	NR	NR	NR	–	NR	NR	–	NR	NR	NR	NR	NR	NR
Plegridy (Peginterferon beta-1a)	Multiple sclerosis, relapsing	Positive	NR	NR	+	–	NR	+	NR	NR	NR	NR	NR	+	NR
Pradaxa (Dabigatran etexilate)	Thromboembolism (venous), prevention	Negative	NR	NR	NR	NR	NR	NR	–	–	NR	NR	NR	NR	NR
Praluent (Alirocumab)	Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia	Positive	NR	NR	NR	–	NR	+	NR	NR	–	NR	NR	NR	NR
Pristiq (Desvenlafaxine succinate)	Depression, MDD	Negative	NR	NR	NR	–	NR	NR	NR	NR	NR	NR	NR	NR	NR
Prolia (Denosumab [Drug Plan Submission])	Osteoporosis, men	Positive	NR	NR	NR	–	NR	+	NR	NR	NR	NR	NR	NR	NR
Prolia (Denosumab)	Osteoporosis, postmenopausal women	Positive	+	NR	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR
Quinsair (Levofloxacin)	Cystic fibrosis with chronic pulmonary <i>Pseudomonas aeruginosa</i> infections	Positive	NR	NR	NR	–	NR	+	+	NR	–	–	NR	–	NR
RAPAFLO (Silodosin)	Prostatic hyperplasia, benign	Negative	NR	NR	NR	–	NR	NR	+	NR	NR	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Ravicti (Glycerol phenylbutyrate)	Urea cycle disorders	Positive	NR	NR	NR	–	NR	NR	+	NR	NR	NR	NR	NR	NR
Rebif (Interferon beta-1a)	Clinically isolated syndrome	Negative	NR	NR	NR	NR	NR	+	NR	–	NR	NR	NR	NR	NR
Relistor (Methylnaltrexone bromide)	Constipation, opioid-induced	Negative	NR	NR	NR	–	NR	NR	NR	–	NR	–	–	NR	NR
Remicade (Infliximab)	Ulcerative colitis	Negative	NR	NR	NR	NR	NR	NR	NR	–	–	–	–	NR	NR
Repatha (Evolocumab)	Primary hyperlipidemia and mixed dyslipidemia	Positive	NR	NR	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR
Resotran (Prucalopride)	Constipation, chronic	Negative	–	NR	NR	–	NR	NR	NR	–	NR	–	NR	NR	NR
Restasis ophthalmic emulsion (Cyclosporine)	Dry eye disease, moderate to moderately severe	Negative	NR	NR	NR	NR	NR	NR	NR	–	NR	NR	NR	NR	NR
Revestive (Teduglutide)	Short bowel syndrome	Positive	NR	NR	NR	–	NR	+	NR	NR	–	NR	NR	NR	NR
Revolade (Eltrombopag olamine)	Thrombocytopenic purpura chronic immune (idiopathic)	Negative	NR	NR	NR	NR	NR	NR	NR	NR	–	NR	NR	NR	NR
Rexulti (Brexiprazole)	Schizophrenia	Positive	NR	NR	NR	–	NR	+	NR	NR	NR	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Rosiver (Ivermectin)	Rosacea	Positive	NR	NR	NR	–	NR	NR	+	NR	NR	NR	NR	NR	NR
Samsca (Tolvaptan)	Hyponatremia, non-hypovolemic	Negative	–	NR	NR	NR	NR	–	NR	–	–	NR	NR	NR	NR
Saphris (Asenapine)	Schizophrenia	Negative	NR	NR	NR	NR	NR	–	–	NR	NR	–	NR	NR	NR
Saphris (Asenapine)	Bipolar I disorder	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Seebri (Glycopyrronium bromide)	COPD, maintenance bronchodilator treatment	Positive	NR	NR	NR	+	NR	+	+	NR	NR	NR	NR	NR	NR
Signifor (Pasireotide diaspertate)	Cushing's disease	Negative	NR	NR	NR	NR	–	NR	NR	–	NR	NR	–	NR	NR
Silkis (Calcitriol)	Psoriasis, mild-to-moderate plaque	Negative	NR	NR	NR	–	NR	NR	–	NR	NR	NR	–	NR	NR
Simponi (Golimumab)	Arthritis, psoriatic	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Simponi (Golimumab)	Ankylosing spondylitis	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Simponi (Golimumab)	Arthritis, rheumatoid	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Soliris (Eculizumab)	Paroxysmal nocturnal hemoglobinuria	Negative	NR	NR	NR	–	NR	+	NR	NR	–	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Spiriva Respimat (Tiotropium bromide)	COPD	Positive	NR	NR	NR	+	NR	+	+	NR	NR	NR	NR	NR	NR
Stelara (Ustekinumab)	Psoriasis	Positive	NR	NR	NR	+	NR	+	+	NR	NR	NR	NR	NR	NR
Strensiq (Asfotase alfa)	Hypophosphatasia, pediatric-onset	Positive	NR	NR	NR	-	+	NR	NR	NR	-	-	NR	NR	NR
Stribild (Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)	HIV-1 infection	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Sublinox (Zolpidem tartrate)	Insomnia, short-term treatment	Negative	NR	NR	NR	NR	NR	NR	-	-	NR	NR	NR	NR	NR
Synjardy (Empagliflozin and metformin)	Diabetes mellitus (type 2)	Positive	NR	NR	NR	+	NR	+	+	NR	NR	NR	NR	NR	NR
Taltz (Ixekizumab)	Psoriasis, moderate-to-severe plaque	Positive	NR	NR	+	-	NR	+	+	NR	-	NR	NR	+	NR
Technivie (Ombitasvir/paritaprevir/ritonavir)	Hepatitis C, chronic (genotype 4)	Positive	+	NR	NR	-	+	NR	NR	NR	-	NR	NR	NR	NR
Toctino (Alitretinoin)	Eczema	Positive	NR	NR	NR	NR	NR	+	NR	NR	NR	-	NR	NR	NR
Toviaz (Fesoterodine fumarate)	Bladder, overactive	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Trajenta (Linagliptin)	Diabetes mellitus, type 2	Positive	NR	NR	NR	+	NR	+	NR	NR	NR	NR	NR	NR	NR
Tresiba (Insulin degludec)	Diabetes mellitus, types 1 and 2	Positive	NR	NR	NR	NR	NR	NR	+	NR	NR	NR	NR	NR	NR
Trulicity (Dulaglutide)	Diabetes mellitus, type 2	Positive	NR	NR	NR	-	NR	NR	+	-	-	NR	NR	NR	NR
Tudorza Genuair (Acidinium bromide)	COPD	Positive	NR	NR	NR	+	NR	+	+	NR	NR	NR	NR	NR	NR
Twynsta (Telmisartan/Amlodipine)	Hypertension, essential	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Uloric (Febuxostat)	Gout	Positive	NR	-	NR	-	NR	NR	+	NR	NR	NR	NR	NR	NR
Ultibro Breezhaler (Indacaterol/glycopyrronium)	COPD	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Uptravi (Selexipag)	Pulmonary arterial hypertension (WHO class II and III)	Positive	NR	NR	NR	-	NR	+	NR	-	-	NR	NR	NR	NR
Viacoram (Perindopril arginine/amlodipine)	Hypertension, essential	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Victoza (Liraglutide)	Diabetes mellitus, type 2	Negative	NR	NR	NR	-	NR	NR	+	NR	NR	NR	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Vimizim (Elosulfase alfa)	Mucopolysaccharidosis IVA (Morquio A syndrome)	Negative	NR	NR	NR	NR	NR	–	NR	–	NR	NR	NR	NR	NR
Vimpat (Lacosamide)	Epilepsy, partial-onset seizures	Positive	NR	NR	NR	–	NR	+	NR	NR	NR	NR	NR	NR	NR
Visanne (Dienogest)	Pain (pelvic) associated with endometriosis	Positive	NR	NR	NR	+	NR	+	+	NR	NR	NR	NR	NR	NR
VPRIV (Velaglucerase alfa)	Gaucher disease	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Vyvanse (Lisdexamfetamine dimesylate)	ADHD	Negative	NR	NR	NR	–	NR	NR	–	–	NR	NR	NR	NR	NR
Xarelto (Rivaroxaban)	Thromboembolic events (venous), pulmonary embolism	Positive	NR	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Xeljanz (Tofacitinib)	Arthritis, rheumatoid	Positive	NR	NR	–	–	NR	+	NR	NR	NR	NR	NR	NR	NR
Xeomin (Clostridium botulinum neurotoxin type A, free from complexing proteins)	Blepharospasm	Positive	NR	NR	+	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Xeomin (Clostridium botulinum neurotoxin type A, free from complexing proteins)	Spasticity, post-stroke	Negative	NR	NR	NR	NR	NR	+	NR	–	NR	NR	–	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Xeomin (Clostridium botulinum neurotoxin type A, free from complexing proteins)	Cervical dystonia	Positive	NR	NR	+	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Xgeva (Denosumab [Drug Plan Submission])	Prevention of skeletal-related events due to bone metastases from other solid tumours (excluding breast and prostate cancer), including non-small-cell lung cancer	Positive	+	NR	NR	+	NR	NR	+	NR	NR	NR	NR	NR	NR
Xgeva (Denosumab [Drug Plan Submission])	Prevention of skeletal-related events due to bone metastases from breast cancer	Positive	NR	NR	NR	-	NR	NR	+	NR	-	NR	NR	NR	NR
Xiaflex (Collagenase clostridium histolyticum)	Dupuytren's contracture with a palpable cord	Positive	NR	NR	+	-	NR	+	NR	NR	NR	-	NR	NR	NR
XigDuo (Dapagliflozin/metformin hydrochloride)	Diabetes mellitus, type 2	Positive	NR	NR	NR	+	NR	+	+	NR	NR	NR	NR	NR	NR
Zaxine (Rifaximin)	Encephalopathy, hepatic	Positive	NR	NR	NR	+	NR	+	NR	NR	+	+	NR	NR	NR

Drug	Indication (from CDR)	CDR recommendation	Patient subgroup evidence	Replacement vs. currently available treatments	Safety or tolerability	Cost	Clinical outcomes from non-comparative trials	Clinical outcomes vs. placebo	Clinical outcomes vs. active comparator	Consistency/certainty in clinical evidence	Incremental cost-effectiveness ratio	Consistency/certainty in economic evidence	Methods used in supporting clinical research	Evidence synthesis methods, only citing use of a network meta-analysis	Evidence synthesis methods, other than a network meta-analysis
Zenhale (inhalation aerosol) (Mometasone furoate and formoterol)	Asthma maintenance (adults, children 12 or older)	Negative	NR	NR	NR	NR	NR	NR	NR	–	NR	NR	–	NR	NR
Zepatier (Elbasvir/grazoprevir)	Hepatitis C, chronic	Positive	+	NR	NR	NR	+	+	NR	NR	+	NR	NR	NR	NR
Zinbrya (Daclizumab beta)	Multiple sclerosis, relapsing	Positive	NR	NR	NR	–	NR	+	+	NR	–	NR	NR	–	NR

+ indicates "Present, in favour of a positive recommendation".

– indicates "Present, in favour of a negative recommendation".

NR indicates that a predictor was "not referenced".

An Exploratory Analysis of Predictors of Concordance between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta

Analyse exploratoire des prédicteurs de la concordance entre les recommandations de remboursement du Programme commun d'évaluation des médicaments et les décisions subséquentes de l'Ontario, de la Colombie-Britannique et de l'Alberta

MICHAEL J. ZORATTI, FENG XIE, KRISTIAN THORLUND, NICOLA ALLEN AND MITCHELL LEVINE

Appendix 4: Summary of predictor evaluations, as assessed from CDR recommendations, arranged by concordance

		Ontario		British Columbia		Alberta	
		Agree	Disagree	Agree	Disagree	Agree	Disagree
Safety or tolerability	Positive	8	0	7	3	8	1
	Negative*	2	0	3	0	3	0
	Not referenced	76	19	107	23	104	18
Cost	Positive	37	1	40	8	45	0
	Negative	24	6	34	14	27	12
	Not referenced	25	12	43	4	43	7
Clinical outcomes vs. placebo	Positive	37	2	42	11	41	10
	Negative*	3	2	7	0	7	0
	Not referenced	46	15	68	15	67	9

		Ontario		British Columbia		Alberta	
		Agree	Disagree	Agree	Disagree	Agree	Disagree
Clinical outcomes vs. active comparator	Positive	36	4	39	11	42	6
	Negative	7	3	15	3	13	2
	Not referenced	43	12	63	12	60	11
Consistency/certainty in clinical evidence	Positive*	0	0	0	0	0	0
	Negative	23	8	35	4	31	6
	Not referenced	63	11	82	22	84	13
Incremental cost-effectiveness ratio	Positive*	5	0	4	0	6	0
	Negative	7	3	14	4	10	3
	Not referenced	74	16	99	22	99	16
Consistency/certainty in economic evidence	Positive*	1	0	0	0	1	0
	Negative	12	3	15	3	14	6
	Not referenced	73	16	102	23	100	13
Methods used in supporting clinical research	Positive*	0	0	0	0	0	0
	Negative	10	3	14	4	16	1
	Not referenced	76	16	103	22	99	18
Patient subgroup-specific evidence, such as population subgroups or previous treatment status*	Positive*	5	0	7	1	5	0
	Negative*	4	3	6	1	6	3
	Not referenced	77	16	104	24	104	16

		Ontario		British Columbia		Alberta	
		Agree	Disagree	Agree	Disagree	Agree	Disagree
Replacement vs. currently available treatments*	Positive*	0	0	0	0	0	0
	Negative*	1	1	2	1	3	0
	Not referenced	85	18	115	25	112	19
Clinical outcomes from non-comparative trials*	Positive*	3	0	5	2	5	0
	Negative*	1	0	1	0	1	0
	Not referenced	82	19	111	24	109	19
Evidence synthesis methods, only citing use of a network meta-analysis*	Positive*	2	0	1	2	3	0
	Negative*	4	0	3	0	4	0
	Not referenced	80	19	113	24	108	19
Evidence synthesis methods, other than a network meta-analysis*	Positive*	0	0	0	0	0	0
	Negative*	0	0	0	0	0	0
	Not referenced	86	19	117	26	115	19

*Excluded from analysis, as summing "Agree" and "Disagree" for each predictor level (positive or negative) yields $n < 10$.